Targeted Therapy for Cancer: Genetic Testing and Side Effects

Targeted therapy for cancer is a form of precision medicine that uses information about a tumor’s genes, proteins, or other features to guide treatment. Genetic and biomarker testing can help identify which patients may benefit and how side effects should be monitored.

Overview

Targeted therapy for cancer refers to medicines that focus on specific molecules involved in the growth, spread, or survival of cancer cells. These molecules may be abnormal genes, altered proteins, or signaling pathways that are more active in cancer cells than in healthy cells. The goal is to select a treatment that is biologically matched to the cancer whenever possible.

This approach is part of precision oncology, in which doctors use laboratory testing, imaging, pathology, and clinical information to personalize care. Targeted therapy may be used alone or together with surgery, radiation therapy, chemotherapy, immunotherapy, or hormone therapy, depending on the cancer type and stage.

Unlike traditional chemotherapy, which often affects many rapidly dividing cells, targeted therapy is designed to interfere with a defined cancer-related process. However, targeted treatments can still affect normal cells and can cause side effects. Careful selection, monitoring, and communication with the oncology team are important parts of treatment.

How Genetic and Biomarker Testing Guides Treatment

Genetic and biomarker testing helps doctors look for features that may predict whether a targeted therapy is likely to work. These tests may identify gene mutations, gene rearrangements, gene amplifications, protein overexpression, or other molecular signals. Examples of commonly tested markers include EGFR, ALK, ROS1, BRAF, HER2, KRAS, NTRK, BRCA1, BRCA2, and several others, depending on the cancer type.

Testing can be performed on a sample of tumor tissue collected during biopsy or surgery. In some situations, a blood test called a liquid biopsy may be used to look for tumor DNA circulating in the bloodstream. Liquid biopsy can be helpful when tumor tissue is difficult to obtain, although a negative result may still need confirmation with tissue testing if clinically appropriate.

There are two broad categories of genetic testing. Somatic testing looks for changes found in the tumor itself and is used mainly to guide cancer treatment. Germline testing looks for inherited genetic changes present in normal cells and may provide information about hereditary cancer risk for the patient and family members. The oncology team can explain which type is needed and whether genetic counseling is recommended.

Test results may show an actionable alteration, no currently targetable change, or a finding of uncertain significance. An actionable result does not always mean a targeted drug is suitable for every patient; doctors also consider cancer stage, previous treatments, organ function, overall health, and the strength of evidence for that specific cancer.

Types of Targeted Cancer Therapies

Targeted therapies include several different medicine groups. Small-molecule inhibitors are often taken by mouth and can enter cells to block enzymes or signaling pathways that cancer cells rely on. Examples include medicines that inhibit tyrosine kinases, BRAF, MEK, CDK4/6, PARP, or other cancer-related targets.

Monoclonal antibodies are laboratory-made proteins that attach to targets on the surface of cancer cells or nearby blood vessels. Some antibodies block growth signals, while others help the immune system recognize cancer cells or deliver treatment directly to them. Antibody-drug conjugates combine an antibody with a cancer-killing medicine, allowing more focused delivery to cells with a specific target.

Other targeted approaches may include medicines that block blood vessel growth, interfere with DNA repair, or affect hormone-related pathways in cancers that depend on hormones. In many cancers, targeted therapy is used only when testing confirms the relevant biomarker. In other cancers, certain targeted medicines may be used based on the cancer type and standard clinical criteria.

The treatment schedule varies widely. Some medicines are taken daily, while others are given by intravenous infusion at planned intervals. The oncology team provides instructions on timing, food interactions, missed doses, monitoring tests, and symptoms that should be reported promptly.

Who May Benefit and What to Expect Before Treatment

Patients most likely to benefit from targeted therapy are those whose cancer has a biomarker that is known to respond to a specific medicine. This is why testing is often recommended before treatment decisions in cancers such as lung cancer, breast cancer, colorectal cancer, melanoma, ovarian cancer, certain leukemias, and many others. Testing recommendations continue to evolve as new evidence becomes available.

Before starting treatment, the oncology team reviews the diagnosis, pathology report, biomarker results, previous therapies, other medical conditions, and current medications. Some targeted medicines can interact with common drugs, supplements, or certain foods. Patients should provide a complete medication list, including non-prescription products.

Baseline tests may include blood counts, liver and kidney function tests, heart evaluation, blood pressure measurement, eye examination, or scans, depending on the chosen medicine. These tests help doctors monitor safety and response during treatment. Follow-up appointments are usually scheduled at regular intervals to assess symptoms, side effects, and cancer control.

Possible Side Effects

Targeted therapy side effects depend on the drug, dose, treatment duration, and the patient’s overall health. Many side effects are manageable when identified early, but they should not be ignored. Patients should report new or worsening symptoms to the care team rather than stopping or changing treatment on their own.

Common side effects may include fatigue, skin rash, dry skin, itching, acne-like changes, nail changes, diarrhea, nausea, mouth sores, loss of appetite, muscle or joint discomfort, and changes in taste. Some medicines can affect liver blood tests, thyroid function, blood sugar, or blood counts. Others may raise blood pressure or increase the risk of bleeding, clotting, or slow wound healing.

Less common but important side effects can involve the lungs, heart, eyes, kidneys, or nerves. Symptoms such as shortness of breath, chest discomfort, significant swelling, yellowing of the skin or eyes, severe diarrhea, vision changes, fever, or a widespread blistering rash require prompt medical assessment. The care team may pause treatment, reduce the dose, prescribe supportive medication, or switch therapy if needed.

Skin care, hydration, nutrition support, blood pressure monitoring, and regular laboratory tests can reduce the impact of many side effects. The exact plan should be individualized because supportive measures that are appropriate for one targeted drug may not be suitable for another.

Treatment Response, Resistance, and Follow-Up

Doctors evaluate whether targeted therapy is working through physical examination, symptom review, blood tests, imaging, and sometimes tumor marker tests. Response may mean that tumors shrink, stop growing, or symptoms improve. In some cases, stable disease can be a meaningful treatment goal, especially when the therapy is well tolerated and the cancer is controlled.

Over time, some cancers develop resistance to targeted therapy. Resistance can occur when cancer cells acquire new genetic changes, activate alternative growth pathways, or when a mixture of cancer cell populations responds differently to treatment. If the cancer begins to grow again, the oncology team may recommend repeat biopsy, liquid biopsy, or additional molecular testing to look for new targets.

Follow-up also focuses on long-term safety. Some targeted drugs can be taken for months or years when effective and tolerable, so regular monitoring is essential. Patients should keep appointments for scans and blood tests even if they feel well, because some treatment effects are detected before symptoms appear.

Changes in treatment do not mean that care has failed. Cancer treatment often involves adjusting the plan as new information becomes available. Options may include another targeted therapy, immunotherapy, chemotherapy, radiation, surgery for selected situations, supportive care, or a clinical trial if appropriate.

Prevention, Self-Care, and When to See a Doctor

There is no universal way to prevent the need for targeted therapy, but general cancer prevention measures remain important. Avoiding tobacco, limiting alcohol, maintaining a healthy weight, staying physically active as tolerated, following vaccination recommendations, and participating in recommended cancer screening can support overall health. For people with inherited cancer risk, genetic counseling and personalized screening plans may be recommended.

During targeted therapy, self-care should focus on safety and consistency. Patients should take medicines exactly as prescribed, store them correctly, avoid missed doses when possible, and ask the care team before using supplements or new medications. A symptom diary can help track rash, bowel changes, fatigue, appetite, blood pressure, or other concerns between visits.

A doctor should be contacted promptly for severe or persistent diarrhea, fever, breathing difficulty, chest pain, fainting, sudden swelling, unusual bleeding, yellowing of the skin or eyes, confusion, vision changes, or a rapidly worsening rash. Patients should also seek medical advice if side effects interfere with eating, drinking, sleeping, or daily activities.

For international patients, Acibadem International provides access to multidisciplinary oncology specialists and JCI-accredited hospitals that diagnose and treat many cancers, including those requiring molecular testing and targeted therapy planning. Treatment decisions should always be made after a full medical evaluation by qualified specialists.

Frequently asked questions

Is targeted therapy the same as chemotherapy?

Targeted therapy and chemotherapy are different treatment approaches. Chemotherapy generally affects rapidly dividing cells, while targeted therapy focuses on specific cancer-related molecules or pathways. Some patients may receive both, depending on the cancer type and treatment plan.

Does every patient need genetic testing before cancer treatment?

Not every patient needs the same type of genetic or biomarker testing. Testing recommendations depend on the cancer type, stage, available treatments, and clinical guidelines. An oncologist can explain whether tumor testing, liquid biopsy, or inherited genetic testing is appropriate.

What happens if genetic testing finds no target?

If testing does not find an actionable target, other effective treatment options may still be available. These may include surgery, radiation therapy, chemotherapy, immunotherapy, hormone therapy, or supportive treatments. The result can also help avoid medicines that are unlikely to help.

Can targeted therapy cure cancer?

In some situations, targeted therapy can be part of treatment with curative intent, especially when combined with other treatments. In advanced cancer, it is often used to control disease, relieve symptoms, and help patients live longer with better quality of life. The expected benefit depends on the cancer and the individual medical situation.

Are targeted therapy side effects milder than chemotherapy side effects?

Targeted therapy side effects are often different from chemotherapy side effects, but they are not always mild. Skin, digestive, liver, blood pressure, heart, lung, or other organ-related effects can occur. Regular monitoring and early reporting help the care team manage side effects safely.

Can a patient stop targeted therapy if side effects occur?

Patients should not stop, skip, or change the dose of targeted therapy without medical advice unless emergency instructions have been provided. The oncology team may recommend supportive care, a temporary pause, dose adjustment, or a different treatment. Prompt communication is the safest way to manage side effects.

References

• National Cancer Institute
• American Society of Clinical Oncology
• European Society for Medical Oncology
• World Health Organization
• National Comprehensive Cancer Network

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.